dolutegravir sodium

FDA Drug Profile — Tivicay PD, Tivicay

dolutegravir sodium is listed in the FDA National Drug Code directory with 22 NDC codes, marketed under brand names including Tivicay PD, Tivicay. Available dosage forms: tablet, for suspension, tablet, film coated, powder.

Drug details

Generic Name
dolutegravir sodium
Brand Names
Tivicay PD, Tivicay
Application Number
NDA213983
Sponsor
ViiV Healthcare Company
NDC Codes
22
Dosage Forms
TABLET, FOR SUSPENSION, TABLET, FILM COATED, POWDER
Routes
ORAL
Active Ingredients
DOLUTEGRAVIR SODIUM

Indications and Usage

1 INDICATIONS AND USAGE TIVICAY and TIVICAY PD are indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor [INSTI]-naïve) aged at least 4 weeks and weighing at least 3 kg [see Microbiology ( 12.4 )]. TIVICAY is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/ mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent. TIVICAY and TIVICAY PD are an HIV-1 integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but INSTI- naïve) aged at least 4 weeks and weighing at least 3 kg. ( 1 ) TIVICAY is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.